EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Antagonists of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) as rationale and therapeutic potential of combination cancer therapy

Hai Qian, Ying Wang, Kwaku Appiah-Kubi

American Journal of Clinical and Experimental Immunology · 2026 · 15 (2) · 148-155

DOI: 10.62347/psyp3847 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Clinical and Experimental Immunology, 2026. Verfasst von Hai Qian und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, Jiangsu University No. 201 Xuefu Road, Zhenjiang 212013, Jiangsu, The People's Republic of China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

PDGF/PDGFRcancer treatmentsco-expressioncombination therapiescross-talkdrug delivery

Autor:innen und Institutionen

  • Department of Physiology, School of Medicine, Jiangsu University No. 201 Xuefu Road, Zhenjiang 212013, Jiangsu, The People's Republic of China.
  • Department of Applied Biology, C. K. Tedam University of Technology and Applied Sciences Navrongo, UK-0215-5321, Ghana.

Zitieren

APA

Qian, H., Wang, Y., & Appiah-Kubi, K. (2026). Antagonists of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) as rationale and therapeutic potential of combination cancer therapy. American Journal of Clinical and Experimental Immunology, 15(2), 148-155. https://doi.org/10.62347/psyp3847

Vancouver

Qian H, Wang Y, Appiah-Kubi K. Antagonists of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) as rationale and therapeutic potential of combination cancer therapy. American Journal of Clinical and Experimental Immunology. 2026;15(2):148-155. doi:10.62347/psyp3847

BibTeX
@article{Qian2026,
  author = {Qian, Hai and Wang, Ying and Appiah-Kubi, Kwaku},
  title = {Antagonists of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) as rationale and therapeutic potential of combination cancer therapy},
  journal = {American Journal of Clinical and Experimental Immunology},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {148--155},
  doi = {10.62347/psyp3847}
}
Kostenlos starten →